FRANKFURT, Oct 23 (Reuters) - Bayer’s finerenone drug slowed the progression of diabetic kidney disease in a late stage clinical trial, underscoring the company’s hopes for the drug to generate at least 1 billion euros ($1.2 billion) in annual sales.
In a Phase III trial, finerenone reduced the risk of either kidney failure, a lasting drop in kidney filtration or death from renal failure by 18%, the German drugmaker said on Friday.
It also reduced the risk of a range of serious cardiovascular conditions by 14%.
The drugs and farming pesticides maker needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer.
Finerenone is an improved version of a troublesome class of heart drugs called mineralocorticoid receptor antagonists (MRAs)that is associated with a range of side effects.
Bayer, which is testing finerenone against a range of other heart and kidney conditions, plans to request marketing approval in diabetic kidney disease by end of this year.
$1 = 0.8505 euros Reporting by Ludwig Burger; Editing by Mark Potter